Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib in previously treated Japanese patients with IDH1-mutated unresectable or metastatic cholangiocarcinoma
jRCT2011230033Phase 2Completed
- Sponsor
- Servier
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib in cholangiocarcinoma (CCA), sponsored by Servier. Primary endpoint: Progression-free survival. Started Sep 2023; status: completed.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2011230033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230033.